- Home
- IOBT vs AVTX Comparison
IOBT vs AVTX Comparison
Compare IOBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- AVTX
- Stock Information
- Founded
- IOBT 2014
- AVTX 2011
- Country
- IOBT Denmark
- AVTX United States
- Employees
- IOBT N/A
- AVTX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- AVTX Health Care
- Exchange
- IOBT Nasdaq
- AVTX Nasdaq
- Market Cap
- IOBT 50.5M
- AVTX 248.3M
- IPO Year
- IOBT 2021
- AVTX 2015
- Fundamental
- Price
- IOBT $0.99
- AVTX $17.86
- Analyst Decision
- IOBT Buy
- AVTX Strong Buy
- Analyst Count
- IOBT 4
- AVTX 9
- Target Price
- IOBT $3.50
- AVTX $30.14
- AVG Volume (30 Days)
- IOBT 9.4M
- AVTX 533.4K
- Earning Date
- IOBT 11-11-2025
- AVTX 11-07-2025
- Dividend Yield
- IOBT N/A
- AVTX N/A
- EPS Growth
- IOBT N/A
- AVTX N/A
- EPS
- IOBT N/A
- AVTX N/A
- Revenue
- IOBT N/A
- AVTX $441,000.00
- Revenue This Year
- IOBT N/A
- AVTX N/A
- Revenue Next Year
- IOBT N/A
- AVTX N/A
- P/E Ratio
- IOBT N/A
- AVTX N/A
- Revenue Growth
- IOBT N/A
- AVTX N/A
- 52 Week Low
- IOBT $0.32
- AVTX $3.39
- 52 Week High
- IOBT $2.79
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- IOBT 51.66
- AVTX 69.10
- Support Level
- IOBT $0.62
- AVTX $15.58
- Resistance Level
- IOBT $1.23
- AVTX $19.40
- Average True Range (ATR)
- IOBT 0.13
- AVTX 1.60
- MACD
- IOBT 0.10
- AVTX 0.25
- Stochastic Oscillator
- IOBT 69.68
- AVTX 72.86
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).